You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1847 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Primary Advanced or Recurrent Endometrial Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Mesothelioma (Peritoneal), 
Lung, 
Mesothelioma (Pleural)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
pemetrexed,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Regimen
Cancer Type:
Gastrointestinal, 
Mesothelioma (Peritoneal), 
Lung, 
Mesothelioma (Pleural)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cemiplimab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
riTUXimab (subcut),
prednisone,
vinCRIStine,
DOXOrubicin,
cyclophosphamide,
iBRUtinib (Unfunded),
CISplatin,
cytarabine,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
DOCEtaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
pembrolizumab (Unfunded),
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Document
Jun 2025
Document
Jun 2025

Pages